

APRIL 2022 MONTHLY HBOT WEBINAR

To Dive or NOT to Dive?

PRESENTED BY DEBORAH WOUND
AND HYPERBARIC CENTER



www.serenagroupinc.com



Comorbidities Overview

- **Comorbidities** are an additional complication to a patient.
- Understand the risk to the patient and how it can be reduced to protect them.
- Pre-treatment testing to help rule out contraindications that may put a patient at risk.
- Working with your overseeing physician to create safe, effective treatment protocol for patients with comorbidities to produce better outcomes.







Comorbidities and Risks

- **COPD (Chronic Obstructive Pulmonary Disorder)** is a respiratory disorder that may have the potential rare side effect of pulmonary barotrauma from lung overinflation. HBOT patients with this comorbidity are at risk for air trapping during decompression with active bronchospasm, mucous plugging and bullous lung disease.
- **CHF (Congestive Heart Failure)** is a condition in which the heart doesn't pump blood as well as it should . Patients with ejection fractions less than 30% are at higher risk for CHF exacerbation and acute pulmonary edema during treatment due to fluid shift because of the pressure increase and decrease. Patients should not be fluid overloaded and a pre-treatment echocardiogram should be considered.

Comorbidities And The Risks



Renal Dialysis – Patients receiving dialysis are at higher risk of HBOT complications due to sudden fluid shifts from volume overload causing pulmonary edema.



Patients on regular **Long-Term Use of High-Flow Oxygen** are at risk of Pulmonary Oxygen Toxicities which could burn the lungs.



Comorbidities And Risks (Drug Risks)

Patients actively being treated for cancer can be eligible to safely receive HBOT although some of the medications may be contraindications which can be discussed during pre-treatment exam.

- **Bleomycin:** Chemotherapy. Pulmonary toxicity is the reason concurrent use of bleomycin and hyperbaric oxygen therapy is contraindicated. *It is considered safe to proceed with hyperbaric oxygen treatment if it has been at least three to four months post bleomycin administration.*
- **Doxorubicin:** Chemotherapy. Cardiac toxicity is the reason concurrent use of doxorubicin and hyperbaric oxygen therapy is contraindicated. *It is considered safe to proceed with hyperbaric oxygen treatment if it has been at least three days post doxorubicin administration.*
- **Cisplatin:** Chemotherapy. Impaired wound healing is the reason concurrent use of Cisplatin and hyperbaric oxygen therapy is contraindicated. *Proceed with treatment in emergent situations and when it has been an extended period from cisplatin administration.*
- **Disulfiram:** Chemotherapy. Blocks superoxide dismutase, which is *protective against oxygen toxicity*
- **Sulfamylon:** Antibacterial agent used in burn patients must be removed before treatment in the Hyperbaric chamber. Impaired wound healing and increased risk of oxygen toxicity is the reason *concurrent use of Sulfamylon and hyperbaric oxygen therapy is contraindicated.*

Pre-treatment Procedures for Success!

- ✓ Always ensure the clearing HBO physician is aware of patient's comorbidities both verbally and by providing all relevant labs, testing and records.
- ✓ Discuss treatment protocol with physician, such as treating at 2.0 ATA
- ✓ Complete all pre-treatment testing ordered in a timely fashion so that it may be carefully reviewed, considered and signed off on by physician.
- ✓ Obtain additional clearances from patient's specialists (cardiac, pulmonology, cardiology, oncology, endocrinology) if requested by clearing physician.
- ✓ Be vigilant during treatment! Watch patient carefully and abort treatment safely if there are any signs of respiratory distress or unusual behavior and address concerns with overseeing physician (whether concerns present pre-tx, during tx, or post tx)

Safe Treatment Protocols

- The clearing HBO physician will determine the treatment protocol. The general recommendation from SerenaGroup for patients that are NOT deemed "at risk" is 2.4 ATA for 90 minutes with two 5 minute air breaks at a rate set of 1.5 psi/min
- "At-risk" patient's treatment plan should be modified to 2.0 ATA (a therapeutic treatment pressure that does not require air breaks) to lower the likelihood of HBOT side effects.
- Rate set should be lowered when patients are new to treatment and are still adjusting to pressure differentials
- Rate set should be lowered when patients have potential air-trapping diseases
- Dr. Serena, Matt Schweyer (SerenaGroup's National Safety Director), and Ally George (Hyperbaric Educator) can work with physicians to answer any questions and achieve best HBOT practices.

QUINZ

Question 1:

A patient with a history of CHF comes in and the physician cleared them for treatment. You take their blood pressure, and it is 225/110 whereas their BP at every other treatment has been between 112-140 systolic and 70-90 diastolic. What should you do *first*?

- A. Dive the patient but keep a watchful eye.
- B. Chart the BP and make sure the physician signs off on it when they complete the notes.
- C. Notify the physician for further instructions before diving the patient.
- D. Wait 15 minutes and retake the BP.
- E. Do not treat the patient that day.

Answer 1

- **FIRST, C**
- Notify the physician for further instructions before diving the patient.
 - After notifying the physician, he or she may say to wait 15 minutes and retake the blood pressure or to not treat them today, but as technicians our first step is to notify the physician.



Question 2

"At-Risk" patients should be treated at _____ ATA unless otherwise determined by the clearing physician.



Answer 2

- 2.0
- If a patient is deemed "at-risk" their treatment protocol should be modified.
- 2.0 ATA is a therapeutic treatment pressure and does not require air breaks.

Question 3

For what comorbidity might a clearing physician request medical clearance by a cardiologist?



Answer 3

- Patients with a history of Congestive Heart Failure

Question 4:

- A patient with COPD and CHF, that has an Ejection Fraction of 40% can NOT receive HBOT.

True or False?

Answer 4

- False
- CHF patients with ejection fractions less than 30%, are at higher risk for CHF exacerbation/acute pulmonary edema during HBOT, therefore should be treated at 2.0 ATA and monitored closely throughout treatments.

To Dive or NOT to Dive

Any questions?

SerenaGroup HBOT Monthly Show Rate

Centers	Program Director	HBO Show Rate
Cleveland Clinic Akron	Nick	
ACMH	Erika	92%
Berkshire	Sean	89%
CHI Health CUMC Bergan	Joe	100%
CHI Health Mercy	Joe	96%
Deborah	Megan	100%
Fairview	Jamie	100%
Henry Ford	Eliece	96%
Jackson	Dean	86%
St. Mary's	Katie	100%
St. Joseph Med Ctr	Christine	100%
Via Christi	Nancy	100%
MH The Woodlands	Andrea	38%
Inspira Health – Elmer	Ally	100%



SerenaGroup Upcoming HBOT Educational Courses

- Introduction to Hyperbaric
April 21-24, 2022, in Akron, OH
- Introduction to Hyperbaric
June 2-5, 2022, in Omaha, NE



Communication is key!

Dr Code & condition	Arterial Studies	30 days tx / ABX	HbA1C	Nutrition	CXR	EKG	Smoking Addressed	Wound Size ↓	Notes
DKED	absent	Wound 1/22	N/A	✓	✓	✓	✓	getting smaller	Denial with treatment after 20 antibiotics, 10k.
Chronic DKED	✓	✓	N/A	nutrition assessment	✓	✓			Active
Radiation neuro.	✓	✓	N/A	N/A	2/7/22	✓		✓	Started 4/7/22 pt changed ins. will resubmit in April
Radiation neuro.	N/A	N/A	N/A	N/A	✓	✓		VA patient	Active
DFU	Successful 10-22-21	✓	3.8	✓	1/13/22	7/13/22	✓		Started 3/2 Need pt consult
DFU	successful 12/21	>30 days	7.45 3.6-22	2/9	clear 2-18-22	Abnormal 2/18/22			Started 2/9
DFU				✓				N/A	Started 3/3
DFU chronic 5/3/20									Started 3/3



Welcome To Hyperbarics!

ACTIVE PATIENTS:	IN PROCESS / CONSULTED*
1.) FF 730 am DFU 27/40	1.)
2.) MK 800 am DFU 20/40	2.) RS Starts 5/2 DFU
3.) DL 1015 am CRO 22/40	3.) TG (Six 4/15 new graft) DFU
4.) CJ 1030 am DFU 42/40	4.) MB consult 4/21 DFU
5.) GH 100 pm CRO 2/30	5.) AK (NLS Next consult 4/12 1:20pm) (Housed apt not resched) DFU
6.) RZ 100 pm RC 19/30	

☺ Happy Easter ☺

HBO Physician: Dr. Reinheimer
HBO Techs: Ashley, Elsa, & Miranda


Time	Name	EOD#	Ins.	Verified	Auth/pt/exp	Projected End Date	Treatment
8:00	Moore		MC	✓	?	5/10	2.4
8:00	Federico		Blue MC Advantage	✓	Pending 4/19		2.4
10:30	S. Jones		MC	✓			
10:30	Ernest		MC	✓			2.4
1:00	Dickerson		MC	✓		5/31	2.0
1:00	Tuck		Clower	✓	30+ exp 7/23/22		2.4
3:30	Enrique		Actna MC	✓	40% exp 9/23/22	5/20	2.0
3:30	Hooper		BC/BS Max	✓	No auth.	4/29	2.4

Bullpen
Green
Anderson May 2022
CenZO 5/2@9:30
Next
- Powell
- S. Smith
- I. Bermejo (insure)

Round Table Discussion

-Chamber room safety is our responsibility

-Anything else



Next Month's Presenter

DATE: May 17, 2022

PRESENTING: Jackson Hospital

TOPIC: Clinical and Non-Clinical
Emergencies



SerenaGroup HBOT Contact Information

Matt Schweyer, Chief Compliance Officer | VP of Compliance, Reimbursement & Safety | National Safety Director

- mschweyer@serenagroups.com
- C. 214-315-5109

SerenaGroup Education Committee

- Ally George = HBO Educator
 - 609-202-6152
 - ageorge@serenagroups.com
- Blair Flinn
- Nancy Trafelet
- Jill Schroder

